All together these data provide evidence that CD146 can increase YAP nuclear translocation and activation of target genes and identifies the Hippo/YAP signaling pathway as a downstream effector of CD146 in enhancing tumor aggressiveness in GBM. This evidence concerns the gene MCAM and glioblastoma.